44 related articles for article (PubMed ID: 16675578)
1. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.
Hande KR; Hagey A; Berlin J; Cai Y; Meek K; Kobayashi H; Lockhart AC; Medina D; Sosman J; Gordon GB; Rothenberg ML
Clin Cancer Res; 2006 May; 12(9):2834-40. PubMed ID: 16675578
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors.
Perez B; Aljumaily R; Marron TU; Shafique MR; Burris H; Iams WT; Chmura SJ; Luke JJ; Edenfield W; Sohal D; Liao X; Boesler C; Machl A; Seebeck J; Becker A; Guenther B; Rodriguez-Gutierrez A; Antonia SJ
ESMO Open; 2024 Feb; 9(2):102217. PubMed ID: 38320431
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro.
Meany HJ; Sackett DL; Maris JM; Ward Y; Krivoshik A; Cohn SL; Steinberg SM; Balis FM; Fox E
Pediatr Blood Cancer; 2010 Jan; 54(1):47-54. PubMed ID: 19731320
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of E7010.
Yamamoto K; Noda K; Yoshimura A; Fukuoka M; Furuse K; Niitani H
Cancer Chemother Pharmacol; 1998; 42(2):127-34. PubMed ID: 9654112
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells.
Mahgoub TM; Jordan EJ; Mahdi AF; Oettl V; Huefner S; O'Donovan N; Crown J; Collins DM
Cancer Chemother Pharmacol; 2024 May; 93(5):427-437. PubMed ID: 38226983
[TBL] [Abstract][Full Text] [Related]
6. Measuring the linear viscoelastic regime of MCF-7 cells with a monolayer rheometer in the presence of microtubule-active anti-cancer drugs at high concentrations.
Lee S; Bashir KMI; Jung DH; Basu SK; Seo G; Cho MG; Wierschem A
Interface Focus; 2022 Dec; 12(6):20220036. PubMed ID: 36330318
[TBL] [Abstract][Full Text] [Related]
7. Improving Homology-Directed Repair in Genome Editing Experiments by Influencing the Cell Cycle.
Smirnikhina SA; Zaynitdinova MI; Sergeeva VA; Lavrov AV
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682671
[TBL] [Abstract][Full Text] [Related]
8. Design, eco-friendly synthesis, molecular modeling and anticancer evaluation of thiazol-5(4
El-Naggar AM; Eissa IH; Belal A; El-Sayed AA
RSC Adv; 2020 Jan; 10(5):2791-2811. PubMed ID: 35496078
[TBL] [Abstract][Full Text] [Related]
9. Strategies for High-Efficiency Mutation Using the CRISPR/Cas System.
Feng S; Wang Z; Li A; Xie X; Liu J; Li S; Li Y; Wang B; Hu L; Yang L; Guo T
Front Cell Dev Biol; 2021; 9():803252. PubMed ID: 35198566
[TBL] [Abstract][Full Text] [Related]
10. Discovery of new quinolines as potent colchicine binding site inhibitors: design, synthesis, docking studies, and anti-proliferative evaluation.
Hagras M; El Deeb MA; Elzahabi HSA; Elkaeed EB; Mehany ABM; Eissa IH
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):640-658. PubMed ID: 33588683
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel
Hussein EM; Al-Rooqi MM; Abd El-Galil SM; Ahmed SA
BMC Chem; 2019 Dec; 13(1):91. PubMed ID: 31384838
[TBL] [Abstract][Full Text] [Related]
12. M3, a natural lignan xyloside, exhibits potent anticancer activity in HCT116 cells.
Shen W; Zhao Y; Chen H; Zhang T; Wu S; Liu P
Oncol Lett; 2019 Feb; 17(2):2117-2122. PubMed ID: 30675278
[TBL] [Abstract][Full Text] [Related]
13. Ways of improving precise knock-in by genome-editing technologies.
Smirnikhina SA; Anuchina AA; Lavrov AV
Hum Genet; 2019 Jan; 138(1):1-19. PubMed ID: 30390160
[TBL] [Abstract][Full Text] [Related]
14. Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site.
Dong M; Liu F; Zhou H; Zhai S; Yan B
Molecules; 2016 Oct; 21(10):. PubMed ID: 27754459
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and anticancer activity of some novel thioureido-benzenesulfonamides incorporated biologically active moieties.
Ghorab MM; Alsaid MS; Al-Dosary MS; Nissan YM; Attia SM
Chem Cent J; 2016; 10():19. PubMed ID: 27057207
[TBL] [Abstract][Full Text] [Related]
16. Enrichment of G2/M cell cycle phase in human pluripotent stem cells enhances HDR-mediated gene repair with customizable endonucleases.
Yang D; Scavuzzo MA; Chmielowiec J; Sharp R; Bajic A; Borowiak M
Sci Rep; 2016 Feb; 6():21264. PubMed ID: 26887909
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.
Rudek MA; Dasari A; Laheru D; He P; Jin R; Walker R; Taylor GE; Jimeno A; Donehower RC; Hidalgo M; Messersmith WA; Purcell WT
J Clin Pharmacol; 2016 Aug; 56(8):966-73. PubMed ID: 26632033
[TBL] [Abstract][Full Text] [Related]
18. Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors.
Oh DY; Kim TM; Han SW; Shin DY; Lee YG; Lee KW; Kim JH; Kim TY; Jang IJ; Lee JS; Bang YJ
Cancer Res Treat; 2016 Jan; 48(1):28-36. PubMed ID: 25715767
[TBL] [Abstract][Full Text] [Related]
19. Exploring natural product chemistry and biology with multicomponent reactions. 5. Discovery of a novel tubulin-targeting scaffold derived from the rigidin family of marine alkaloids.
Frolova LV; Magedov IV; Romero AE; Karki M; Otero I; Hayden K; Evdokimov NM; Banuls LM; Rastogi SK; Smith WR; Lu SL; Kiss R; Shuster CB; Hamel E; Betancourt T; Rogelj S; Kornienko A
J Med Chem; 2013 Sep; 56(17):6886-900. PubMed ID: 23927793
[TBL] [Abstract][Full Text] [Related]
20. Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.
Innocenti F; RamÃrez J; Obel J; Xiong J; Mirkov S; Chiu YL; Katz DA; Carr RA; Zhang W; Das S; Adjei A; Moyer AM; Chen PX; Krivoshik A; Medina D; Gordon GB; Ratain MJ; Sahelijo L; Weinshilboum RM; Fleming GF; Bhathena A
Pharmacogenet Genomics; 2013 Jul; 23(7):374-81. PubMed ID: 23670235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
